LEADING A RENAISSANCE

IN KIDNEY DISEASE

TREATMENT

Main-Banner-v3B-01.jpg

 

FOCUS

 

Banners-05.png

Goldfinch is singularly focused on discovering and developing precision therapies for patients with kidney disease.

Chronic kidney disease is a driver of mortality across age, race, and stage of disease progression, affecting over 1 in 9 people worldwide. It has emerged as a global epidemic and growing problem that places an enormous social and economic burden on patients, their families, and society.

Advances in kidney transplantation and dialysis over half a century ago extended life for patients with kidney failure, yet the current standard of care for patients with kidney disease remains inadequate, and there is an urgent need for new treatment options.

Recent breakthroughs in genetics and biology have generated an unparalleled understanding of the biological pathways that drive kidney disease. Goldfinch is uniquely positioned to translate these discoveries into new therapies that target the molecular causes of kidney disease.

 

The burden of kidney disease for patients and society

 

TEAM

 

Banners-07.png

Goldfinch brings together experts in the field and experienced leaders with a shared mission to pioneer new treatments for patients with kidney disease.

LEADERSHIP

Anthony Johnson, M.D.

Chief Executive Officer

Michael Broxson

Chief Business and Operating Officer

Peter Mundel, M.D.

Chief Scientific Officer

Jean-Christophe Harmange, Ph.D.

Senior Vice President of Drug Discovery

Lori Rudolph-Owen, Ph.D.

Senior Vice President of Portfolio Leadership

Maria Beconi, Ph.D.

Vice President of Pharmacology and Non Clinical Development

Curtis Demick

Vice President of Human Resources

Thomas Tibbitts, Ph.D.

Vice President of Computational Discovery

Liron Walsh, M.D.

Vice President of Translational and Clinical Nephrology

FOUNDERS AND ADVISORS

Our Founders and Advisors are world-renowned scientists and clinicians at the forefront of kidney biology, genetics, and genomics.

Joseph Bonventre, M.D., Ph.D.

Harvard Medical School, MIT, Brigham and Women's Hospital

Anna Greka, M.D., Ph.D.

The Broad Institute, Harvard Medical School, Brigham and Women’s Hospital

Friedhelm Hildebrandt, M.D.

Harvard Medical School, Boston Children's Hospital

Daniel MacArthur, Ph.D.

The Broad Institute, Harvard Medical School, Massachusetts General Hospital

Peter Mundel, M.D.

Goldfinch Bio

Stefan Somlo, M.D.

Yale School of Medicine

BOARD OF DIRECTORS

Abbie Celniker, Ph.D.

Chairwoman of Goldfinch Bio and Partner, Third Rock Ventures

Louis Brenner, M.D.

President and Chief Operating Officer, Allena Pharmaceuticals

Neil Exter

Partner, Third Rock Ventures

Anthony Johnson, M.D.

Chief Executive Officer

Frank W. Maddux, M.D., F.A.C.P.

Executive Vice President and Chief Medical Officer, Fresenius Medical Care North America

 

APPROACH

 

Banners-06.png

Goldfinch is integrating breakthroughs in kidney genetics and biology to identify new therapeutic targets and advance first-in-class drug candidates to treat patients with kidney disease.

 
 

Goldfinch’s Product Engine will industrialize the integration of genetics and kidney biology and confer a differentiated ability to identify, validate, and pursue novel therapeutic targets for kidney disease.

 

PROGRAMS

 

Banners-08.png

Goldfinch’s therapeutic programs are underscored by strong genetic validation and a deep familiarity of the biological pathways that cause disease. Our initial efforts are focused on focal segmental glomerulosclerosis (FSGS) and polycystic kidney disease (PKD).


FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)

Programs-02-v2-01.png

Focal Segmental Glomerulosclerosis (FSGS), a rare kidney disorder, is a histopathologic diagnosis characterized by severe scarring of the kidney's filtering units, or glomeruli, leading to an excess of essential proteins spilling into the urine, called proteinuria. FSGS is a leading cause of kidney failure, and patients with diagnosed FSGS are at increased risk of heart attack, stroke and premature death.

There are currently no FDA approved treatments for FSGS. Existing treatments are non-specific, do not alter the progression of disease and carry significant toxicities.

Goldfinch is leading the charge to develop treatments targeting the molecular causes of FSGS to drastically improve the lives of patients suffering from this devastating, life-shortening condition.


POLYCYSTIC KIDNEY DISEASE (PKD)

Programs-02-v2-01.png

Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common single gene diseases, affecting more than 600,000 people in the US and 12 million worldwide. The disease is passed on from parent to child, with each child of an affected parent having a 1-in-2 chance of inheriting the disorder, which does not skip generations.

ADPKD patients develop fluid filled cysts in both kidneys that increase in number and size over time, culminating in end stage kidney disease in half of affected individuals by middle age. ADPKD commonly causes liver cysts which arise from bile ducts and can sometimes grow large enough to cause symptoms as well. In the United States, 1 in 20 individuals either on dialysis or with a kidney transplant has ADPKD.

There are no FDA approved therapies specifically targeting ADPKD and no means by which to alter the course of the disease.

Goldfinch is leveraging scientific discoveries based on the known genes that cause ADPKD to discover treatments to alter the course of ADPKD and drastically improve the lives of patients suffering from this chronic and debilitating disease.

 

Patients

 

Banners-05.png

It is the patients with kidney disease who will lead us to the understanding of pathways and targets that will drive transformative drug development. To accomplish this, we will partner with patients to build the world’s most comprehensive registry of individuals with molecularly defined kidney disease.

Goldfinch is assembling a database of genetic, genomic and clinical information from consented patients who have provided thousands of DNA samples and anonymized clinical records. Building off of the studies of our founders and partners, we will deeply study DNA and correlate findings with clinical data. We will then use novel computational tools to mine for evidence of the DNA variants that increase risk for kidney disease and suggest new ways to treat and prevent it.

 

CAREERS

 

Banners-06.png

At Goldfinch, we are pioneering a new approach to discover and develop therapeutics for kidney disease that is unprecedented.

Where others see risk, we see opportunity to make an impact and redefine the state of care for patients with kidney disease. We recognize the importance of collaboration, and strive to work alongside patients, clinicians and other partners to empower patients and develop treatments for conditions where no approved therapies exist.

We’re looking for teammates who relish the challenge, and are compelled to leave a positive mark on the lives of colleagues and patients alike.

If this sounds like the community you want to grow with, we invite you to explore our current career opportunities below.

If you would like to be considered for an opportunity at Goldfinch Bio, please submit your CV with the title of the position in the subject line to careers@goldfinchbio.com.

JOIN THE RENAISSANCE

Principal Scientist, Biomarker and Translational Research

The Role

We’re seeking a highly motivated Principal Scientist with a strong background in disease characterization and biomarker technology to join our Pharmacology and Translational Science Department to contribute to building our pipeline for renal diseases. The successful candidate will focus on the discovery and progression of novel biomarkers and therapeutics for Goldfinch programs. Responsibilities include leading scientific research to identify, evaluate, and characterize relevant blood, urine, and kidney biomarkers that will provide useful pharmacodynamic and efficacy endpoints in preclinical and clinical settings.

Major Responsibilities

  • Develop strategy and scientific approach to identify novel diagnostic, prognostic, and pharmacodynamic biomarkers to enable scientific driven go/no go decisions for programs to assist in program progression.
  • Develop in vitro and biochemical assays to evaluate efficacy, PK/PD relationship, and novel biomarkers to characterize molecules for potential therapeutic effects.
  • Lead the identification and validation of novel biomarkers to enable scientific driven go/no go decisions for programs to assist in program progression.
  • Establish and manage external research collaborations to identify diagnostic and prognostic biomarkers for indications of interest in chronic kidney disease.
  • Participate in and lead cross-functional teams to support preclinical drug discovery and development.
  • Prepare, review and deliver high quality scientific presentations for internal/external use.
  • Commitment to help the team achieve deliverables and meet aggressive timelines.

Requirements and Qualifications

  • PhD with at least 6 years post-degree research in an industry setting.
  • Extensive hands-on experience with biomarker technology platforms, including untargeted and targeted mass spectrometry, ELISA, etc.
  • Hands-on experience in cellular and biochemical science such as standard molecular biology and protein biochemistry techniques.
  • Hands on experience in the development and validation of biomarker assays in the preclinical and clinical setting required.
  • Strong publication record and demonstrated experience conducting independent research, preferably in the field of monogenic diseases
  • Strong leadership and evidence of strategic scientific thinking.
  • Effective managerial skills and the ability to lead independent scientists with different skill sets.
  • Expertise in cutting edge assay technologies and proven assay troubleshooting skills.

Sr. Director / VP of Biology

The Role

We seek an energetic and highly driven scientist to direct our internal research and collaborations around cell biology in support of our human kidney disease production engine. A major responsibility of this role includes the biological validation of novel genetic variants identified through our Kidney Patient Registry. In addition, the successful candidate will oversee and further develop our IPSC and kidney organoid efforts.

Major Responsibilities

  • She/he will oversee our rapidly evolving portfolio, lead and develop talented scientists, and oversee the creation or adaptation of in vitro assays to enable drug discovery efforts
  • Develop/co-develop the overall strategy and lead our cell biology team in the discovery of actionable insights into kidney-disease causing genetic variants
  • Oversee the evolution our existing internal lab component (podocyte biology and kidney organoid platform), including the development, implementation and execution of in vitro and in vivo assays required for the advancement of high priority projects and Goldfinch Bio's product engine
  • Guide biological experiments in support of program objectives and translational sciences for multiple therapeutic areas

Requirements and Qualifications

  • Ph.D. or M.D. with 10 or more years industry experience, including extensive leadership experience, managing teams of scientists
  • A strong background in cell biology with an emphasis on Rho GTPase biology is strongly preferred
  • Demonstrated success with target identification and validation
  • Experience developing people and mentoring project leaders
  • Experience building biology groups in a start-up biotech / pharmaceutical company is preferred

Senior Computational Chemist

The Role

Goldfinch Bio is looking for an energetic and highly-driven computational chemist that is committed to creating novel therapies for a critical unmet need. This position will collaborate closely with scientists across the company to maximize the impact of computational methods on drug discovery projects. A key focus of this role will be to work closely with our team of medicinal chemists to support hit to lead and lead optimization, to apply structure-based virtual screening to drug new targets and model the impact of new mutations identified through Goldfinch Bio’s patient registry.

Major Responsibilities

  • Provide computational chemistry support to on-going drug discovery projects using a broad spectrum of structure-based drug design and cheminformatics techniques and analyses
  • Apply molecular dynamics and other simulation techniques to understand structural differences between on- and off-targets, and molecular recognition of small molecule inhibitors
  • Carry out analyses that combine computational and experimental data to develop testable hypotheses that drive drug discovery programs
  • Perform virtual screening to identify compounds of interest in new development areas

Requirements and Qualifications

  • Ph. D in Computational Chemistry or related discipline with at least 5 years industrial/post-doctoral experience
  • Experience with docking and virtual screening of compounds using protein crystal structures (preferably using MOE)
  • Cheminformatics experience, including analysis and visualization of multi-dimensional data sets
  • Experience analyzing high throughput screening data, including large-scale compound screens
  • Proven expertise in in-silico drug design, drug target assessment and SAR analysis
  • Applied experience with machine learning techniques a plus
  • Proficient programming skills, preferably in python
  • Excellent communication skills. Ability to communicate in an open, clear, timely and consistent manner

Part Time Bioinformatics Developer (Contract)

The Role

Goldfinch Bio is looking for a part-time, energetic intern to help us manage some of the software engineering demands within our Computational Research department. The position will require a commitment of 10-15 hours per week for at least the next 3 months. This is a great opportunity to leverage your experience and skills to make a significant impact in the research and clinical programs at Goldfinch while gaining real-world experience in a corporate environment. The individual in this position will work closely with our Clinical department to analyze patient data along with genetic data to push towards our goal of a personalized medicine approach to treating patients with kidney disease.

Skills

  • Bioinformatics, Computer Science or similar discipline is required
  • Strong programmer with proven experience working in Python
  • Great attention to detail, and the ability to critically evaluate data that your code produces
  • The ability to communicate with non-technical personnel and the capacity to translate requests into actionable software requirements

An Ideal Candidate Has

  • An undergraduate degree, and is enrolled in a local graduate program
  • Experience with data visualization in Spotfire
  • Experience with version control, preferably git
  • Experience working with Docker and/or AWS ECR
  • Experience writing unit tests in Python
  • Experience with relational and non-relational databases
  • Experience working in Amazon Web Services
  • A public code repository demonstrating experience with programming in Python

Note to Recruitment Agencies: Please do not forward any agency resumes. Goldfinch Bio is not responsible for any fees related to resumes that are unsolicited.
 
Equal Opportunity Employer M/F/D/V.